Song N G, Yang W Q, Wang C J, Xu Z C, Guo B Q, Wei M J
Clinical Laboratory Department, No. 255 Hospital, PLA, Tangshan, Hebei, China.
Clin Lab Sci. 1997 Nov-Dec;10(6):325-8.
To estimate the stability and reliability of lipoprotein(a) cholesterol measurement, and explore the possibility to evaluate lipoprotein(a) excess in plasma by using lipoprotein(a)-cholesterol assay alternatively to assay lipoprotein(a).
Number 255 Hospital of PLA, Tangshan, Hebei, China.
A total of 396 plasma samples from 100 healthy people (control), 107 chronic renal failure patients, 114 coronary heart disease patients, and 75 cerebral infarction patients, respectively, were measured for lipoprotein(a) cholesterol and lipoprotein(a) mass; lipoprotein(a) cholesterol and lipoprotein(a) mass levels among control and diseased groups were compared; and lipoprotein(a) cholesterol levels and lipoprotein(a) mass values from the control group were subjected to linear regression analysis.
The affinity between oligosaccharide contained in lipoprotein(a) and lectin wheat germ agglutinin to isolate lipoprotein(a) from other lipoproteins; lipoprotein(a) cholesterol and lipoprotein(a) mass detected by total cholesterol kits and enzyme linked immunosorbent assay kits, respectively.
Both lipoprotein(a) cholesterol and lipoprotein(a) mass levels of the chronic renal failure, coronary heart disease, and cerebral infarction groups were significantly higher than those of the control (P < 0.05 or P < 0.01) whereas no difference was seen among the diseased groups at the 0.05 level. Regression analysis within the control group showed a very high correlation between lipoprotein(a) cholesterol and lipoprotein(a) (r = 0.9932).
The results suggest that lipoprotein(a) cholesterol assay may be used in the place of lipoprotein(a) measurement for evaluating lipoprotein(a) excess for chronic renal failure, coronary heart disease, and cerebral infarction patients. Further studies about the mechanism of this association between lipoprotein(a) cholesterol and lipoprotein(a) levels are needed.
评估脂蛋白（a）胆固醇测量的稳定性和可靠性，并探索使用脂蛋白（a）胆固醇检测替代脂蛋白（a）检测来评估血浆中脂蛋白（a）过量的可能性。
中国河北唐山解放军第255医院。
分别对来自100名健康人（对照组）、107名慢性肾衰竭患者、114名冠心病患者和75名脑梗死患者的396份血浆样本进行脂蛋白（a）胆固醇和脂蛋白（a）质量检测；比较对照组和疾病组之间的脂蛋白（a）胆固醇和脂蛋白（a）质量水平；并对对照组的脂蛋白（a）胆固醇水平和脂蛋白（a）质量值进行线性回归分析。
脂蛋白（a）中所含寡糖与凝集素麦胚凝集素之间的亲和力，以从其他脂蛋白中分离出脂蛋白（a）；分别用总胆固醇试剂盒和酶联免疫吸附测定试剂盒检测脂蛋白（a）胆固醇和脂蛋白（a）质量。
慢性肾衰竭组、冠心病组和脑梗死组的脂蛋白（a）胆固醇和脂蛋白（a）质量水平均显著高于对照组（P < 0.05或P < 0.01），而在0.05水平上疾病组之间未见差异。对照组内的回归分析显示脂蛋白（a）胆固醇与脂蛋白（a）之间具有非常高的相关性（r = 0.9932）。
结果表明，对于慢性肾衰竭、冠心病和脑梗死患者，脂蛋白（a）胆固醇检测可用于替代脂蛋白（a）测量来评估脂蛋白（a）过量。需要进一步研究脂蛋白（a）胆固醇与脂蛋白（a）水平之间这种关联的机制。
